Published in Hypertension on December 13, 2004
Medication nonadherence: an unrecognized cardiovascular risk factor. MedGenMed (2007) 1.73
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest (2007) 1.41
Resistant hypertension workup and approach to treatment. Int J Hypertens (2010) 0.94
Genetic and Adverse Health Outcome Associations with Treatment Resistant Hypertension in GenHAT. Int J Hypertens (2013) 0.92
Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans. Pharmacogenomics J (2008) 0.91
Prevalence and risk factors for resistant hypertension among hypertensive patients from a developing country. BMC Res Notes (2013) 0.83
Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans? BMC Med Genet (2010) 0.83
Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine. Curr Pharmacogenomics Person Med (2011) 0.83
CYP3A5 polymorphism, amlodipine and hypertension. J Hum Hypertens (2013) 0.79
A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes. J Biopharm Stat (2008) 0.78
Association between -T786C NOS3 polymorphism and resistant hypertension: a prospective cohort study. BMC Cardiovasc Disord (2009) 0.78
Genetic architecture of complex traits predisposing to nephropathy: hypertension. Semin Nephrol (2010) 0.76
Association between urinary 6β-hydroxycortisol/cortisol ratio and CYP3A5 genotypes in a normotensive population. Exp Ther Med (2012) 0.75
Pregnane X receptor and yin yang 1 contribute to the differential tissue expression and induction of CYP3A5 and CYP3A4. PLoS One (2012) 0.75
CYP3A5 as a candidate gene for hypertension: no support from an unselected indigenous West African population. J Hum Hypertens (2016) 0.75
Genome-wide study of resistant hypertension identified from electronic health records. PLoS One (2017) 0.75
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
The chromogranin-secretogranin family. N Engl J Med (2003) 4.28
Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet (2002) 3.95
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther (2004) 3.84
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther (2003) 3.71
Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2005) 3.63
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat (2004) 3.40
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology (2004) 3.27
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol (2010) 3.21
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene (2003) 2.82
Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res (2006) 2.63
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol (2011) 2.47
Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol (2007) 2.45
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol (2005) 2.41
Neuroendocrine nicotinic receptor activation increases susceptibility to bacterial infections by suppressing antimicrobial peptide production. Cell Host Microbe (2010) 2.39
Determination of split renal function by 3D reconstruction of CT angiograms: a comparison with gamma camera renography. AJR Am J Roentgenol (2008) 2.30
Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer (2004) 2.22
Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest (2005) 2.19
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol (2010) 2.15
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med (2008) 2.05
Common genetic variants of the human uromodulin gene regulate transcription and predict plasma uric acid levels. Kidney Int (2013) 2.05
Ethnic differences in urine concentration: possible relationship to blood pressure. Clin J Am Soc Nephrol (2007) 1.97
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Improved patient survival after acute variceal bleeding: a multicenter, cohort study. Am J Gastroenterol (2003) 1.95
Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat (2007) 1.92
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol (2012) 1.91
Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol (2008) 1.91
A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese. Hum Mol Genet (2011) 1.91
Tyrosine hydroxylase, the rate-limiting enzyme in catecholamine biosynthesis: discovery of common human genetic variants governing transcription, autonomic activity, and blood pressure in vivo. Circulation (2007) 1.91
Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther (2004) 1.89
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics (2007) 1.84
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J Pharmacol Exp Ther (2006) 1.84
The neuroendocrine peptide catestatin is a cutaneous antimicrobial and induced in the skin after injury. J Invest Dermatol (2008) 1.79
Germline pharmacogenetics of tamoxifen response: have we learned enough? J Clin Oncol (2007) 1.76
Trends in mortality from cancers of the breast, colon, prostate, esophagus, and stomach in East Asia: role of nutrition transition. Eur J Cancer Prev (2012) 1.73
Chromogranin A polymorphisms are associated with hypertensive renal disease. J Am Soc Nephrol (2008) 1.68
G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions. Am J Hypertens (2009) 1.66
Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology (2003) 1.65
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics (2008) 1.65
Population-based sample reveals gene-gender interactions in blood pressure in White Americans. Hypertension (2006) 1.64
Polymorphisms and haplotypes of the regulator of G protein signaling-2 gene in normotensives and hypertensives. Hypertension (2006) 1.61
Differential gene induction by type I and type II interferons and their combination. J Interferon Cytokine Res (2006) 1.61
Autonomic and hemodynamic origins of pre-hypertension: central role of heredity. J Am Coll Cardiol (2012) 1.59
Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry (2008) 1.59
Both rare and common polymorphisms contribute functional variation at CHGA, a regulator of catecholamine physiology. Am J Hum Genet (2004) 1.58
Animal versus plant protein meals in individuals with type 2 diabetes and microalbuminuria: effects on renal, glycemic, and lipid parameters. Diabetes Care (2002) 1.58
Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS Comput Biol (2012) 1.58
Chromogranin A regulates renal function by triggering Weibel-Palade body exocytosis. J Am Soc Nephrol (2009) 1.55
Stone fragmentation during shock wave lithotripsy is improved by slowing the shock wave rate: studies with a new animal model. J Urol (2002) 1.55
Effects of chromogranin A deficiency and excess in vivo: biphasic blood pressure and catecholamine responses. J Hypertens (2010) 1.54
Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res (2006) 1.53
Reversed diastolic flow in the renal transplant: perioperative implications versus transplants older than 1 month. AJR Am J Roentgenol (2008) 1.53
Airflows around oxygen masks: A potential source of infection? Chest (2006) 1.53
Internal hernia after gastric bypass: sensitivity and specificity of seven CT signs with surgical correlation and controls. AJR Am J Roentgenol (2007) 1.53
Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res (2004) 1.53
Genetic variation at the human alpha2B-adrenergic receptor locus: role in blood pressure variation and yohimbine response. Hypertension (2005) 1.52
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos (2002) 1.52
Drug interactions with herbal products and grapefruit juice: a conference report. Clin Pharmacol Ther (2004) 1.51
Functional allelic heterogeneity and pleiotropy of a repeat polymorphism in tyrosine hydroxylase: prediction of catecholamines and response to stress in twins. Physiol Genomics (2004) 1.51
Adrenergic beta-1 receptor genetic variation predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis. Nephrol Dial Transplant (2009) 1.49
A Poisson mixture model to identify changes in RNA polymerase II binding quantity using high-throughput sequencing technology. BMC Genomics (2008) 1.49
Independent influence of dietary protein on markers of kidney function and disease in obesity. Kidney Int (2010) 1.48
Kidney damage and renal functional changes are minimized by waveform control that suppresses cavitation in shock wave lithotripsy. J Urol (2002) 1.47
A common genetic variant in the 3'-UTR of vacuolar H+-ATPase ATP6V0A1 creates a micro-RNA motif to alter chromogranin A processing and hypertension risk. Circ Cardiovasc Genet (2011) 1.47
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst (2012) 1.46
Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer (2004) 1.45
Dopamine D1 receptor (DRD1) genetic polymorphism: pleiotropic effects on heritable renal traits. Kidney Int (2009) 1.44
The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther (2004) 1.44
Acute pancreatitis: computed tomography utilization and radiation exposure are related to severity but not patient age. Clin Gastroenterol Hepatol (2009) 1.43
Genes and environment: novel, functional polymorphism in the human cathepsin L (CTSL1) promoter disrupts a xenobiotic response element (XRE) to alter transcription and blood pressure. J Hypertens (2012) 1.41
Exhaled air dispersion distances during noninvasive ventilation via different Respironics face masks. Chest (2009) 1.41
Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat (2007) 1.41
Reduced methadone clearance during aromatase inhibition. J Clin Psychopharmacol (2012) 1.39